目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 EMPTY CAPSULES MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 UNITS CONSIDERED
1.3.4.1 Currency/Value units
1.3.4.2 Volume units
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.1.1 SECONDARY DATA
2.1.1.1 Key sources of secondary data
2.1.1.2 Key objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 GLOBAL EMPTY CAPSULES MARKET ESTIMATION, 2024
2.2.1.1 Company revenue analysis (bottom-up approach)
2.2.1.2 Volume-based estimation
2.2.1.3 MNM repository analysis
2.2.1.4 Primary research
2.2.2 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY
3.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN EMPTY CAPSULES MARKET
3.3 DISRUPTIVE TRENDS SHAPING EMPTY CAPSULES MARKET

4 PREMIUM INSIGHTS
4.1 SNAPSHOT: GLOBAL EMPTY CAPSULES MARKET, CAGR, AND FORECAST (2025-2030)
4.2 NORTH AMERICA: EMPTY CAPSULES MARKET, BY TYPE AND COUNTRY (2024)
4.3 EMPTY CAPSULES MARKET, BY THERAPEUTIC APPLICATION (2024)
4.4 EMPTY CAPSULES MARKET, BY END USER (2024)
4.5 EMPTY CAPSULES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing demand for nutraceuticals and personalized supplements
5.2.1.2 Growing focus on pharmaceutical development and increase in clinical trials
5.2.1.3 Increased demand for functional and modified-release capsules in pharmaceutical and nutraceutical industries
5.2.1.4 Advancements in capsule delivery technologies
5.2.1.5 Shift toward vegetarian, vegan, and clean-label capsules
5.2.1.6 Growing preference for self-medication and OTC drugs
5.2.2 RESTRAINTS
5.2.2.1 Dietary restrictions associated with gelatin consumption
5.2.2.2 Issues related to safety and efficacy of gelatin capsules
5.2.2.3 Competition from alternative drug delivery technologies
5.2.3 OPPORTUNITIES
5.2.3.1 Geographic expansion and localized production in emerging economies
5.2.3.2 Development of biodegradable and sustainable capsules in life sciences industry
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with logistics and storage of empty capsules
5.2.4.2 Lack of adequate raw material and increased supply chain dependence
5.3 INDUSTRY TRENDS
5.3.1 AI-INTEGRATED AND PERSONALIZED DRUG AND SUPPLEMENT FORMULATION AND DOSING
5.3.2 ON-DEMAND MANUFACTURING SYSTEMS AND DECENTRALIZED CAPSULE-BASED FORMULATIONS IN CLINICAL TRIALS
5.3.3 INTEGRATION OF SMART CAPSULES AND INGESTIBLE SENSORS IN CLINICAL RESEARCH
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF EMPTY CAPSULES, BY TYPE, 2022-2024
5.5.2 AVERAGE SELLING PRICE TREND OF EMPTY CAPSULES, BY REGION, 2022-2024
5.5.3 FACTORS IMPACTING EMPTY CAPSULES PRICING
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 Advanced quality control systems
5.6.1.2 Automated encapsulation machines
5.6.2 COMPLEMENTARY TECHNOLOGIES
5.6.2.1 3D printing
5.6.2.2 Enteric capsule technologies
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 Nanotechnology
5.6.3.2 AI in capsule manufacturing
5.7 VALUE CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
5.8.1 RAW MATERIAL VENDORS
5.8.2 PRODUCT PROVIDERS
5.8.3 END USERS
5.8.4 REGULATORY AUTHORITIES
5.8.5 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFT
5.9 PORTER'S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 KEY STAKEHOLDERS & BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.10.2 KEY BUYING CRITERIA
5.10.3 ADOPTION BARRIER & INTERNAL FRICTION
5.11 PATENT ANALYSIS
5.11.1 PATENT METHODOLOGY
5.11.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
5.11.3 INNOVATION & PATENT APPLICATIONS
5.11.4 TOP APPLICANTS
5.11.5 INDICATIVE LIST OF PATENTS
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 TRADE ANALYSIS
5.13.1 IMPORT AND EXPORT DATA FOR HS CODE 960200
5.13.1.1 Import data for HS code 960200, 2020-2024
5.13.1.2 Export data for HS code 960200, 2020-2024
5.13.2 IMPORT AND EXPORT VOLUME FOR HS CODE 960200
5.13.2.1 Import volume for HS code 960200, 2020-2024
5.13.2.2 Export volume for HS code 960200, 2020-2024
5.14 TARRIF DATA & REGULATORY ANALYSIS
5.14.1 TARIFF DATA ANALYSIS
5.14.2 REGULATORY FRAMEWORK
5.14.2.1 Manufacturing process standards
5.14.2.2 Regulations for capsule supplier change
5.14.2.3 Regulatory information on colorants
5.14.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.4 REGULATORY CHALLENGES
5.14.5 SUSTAINABILITY IMPACT
5.15 CUSTOMER LANDSCAPE
5.15.1 UNMET NEEDS & WHITE SPACES
5.15.2 CAPSULE PURCHASE/PROCUREMENT MODELS
5.15.3 BUDGET ALLOCATION TREND
5.15.4 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
5.16 INVESTMENT & FUNDING SCENARIO
5.17 IMPACT OF AI/GEN AI ON EMPTY CAPSULES MARKET
5.17.1 MARKET POTENTIAL OF AI IN EMPTY CAPSULES PRODUCTION
5.17.2 AI USE CASES
5.17.3 KEY COMPANIES IMPLEMENTING AI
5.17.4 FUTURE OF GENERATIVE AI IN EMPTY CAPSULES ECOSYSTEM
5.18 IMPACT OF 2025 TRUMP TARIFF ON EMPTY CAPSULES MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 IMPACT ON COUNTRY/REGION
5.18.4.1 North America
5.18.4.1.1 US
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON END-USE INDUSTRIES
5.18.5.1 Pharmaceutical & biotech companies
5.18.5.2 Nutraceutical industry
5.18.5.3 Cosmetic industry
5.19 EMPTY CAPSULES MANUFACTURING PROCESS
5.19.1 SOURCING OF RAW MATERIAL
5.19.1.1 Identify source
5.19.1.2 Impact of source variation on product quality
5.19.1.3 Certification for sustainable and ethical sourcing
5.19.1.4 Impact of market dynamics on raw material sourcing
5.19.1.5 Role of industry associations on raw material sourcing
5.19.2 PROCESSING
5.19.3 QUALITY CONTROL & PACKAGING
5.20 EMPTY CAPSULES PRODUCTION CAPACITY
5.21 INTERCONNECTED MARKET: INSIGHTS ON PHARMACEUTICAL GELATIN MARKET

6 EMPTY CAPSULES MARKET, BY TYPE
6.1 INTRODUCTION
6.2 GELATIN CAPSULES
6.2.1 PROVEN SAFETY, VERSATILITY, EASE OF MANUFACTURING, QUICK DISINTEGRATION, AND HIGH BIOAVAILABILITY TO DRIVE ADOPTION
6.2.2 GELATIN EMPTY CAPSULES VOLUME MARKET, BY REGION
6.3 NON-GELATIN CAPSULES
6.3.1 SHIFT OF CONSUMER DEMAND TOWARD CLEAN-LABEL, VEGAN, AND SUSTAINABLE SOLUTIONS TO PROPEL MARKET GROWTH
6.3.2 NON-GELATIN EMPTY CAPSULES VOLUME MARKET, BY REGION

7 EMPTY CAPSULES MARKET, BY RAW MATERIAL
7.1 INTRODUCTION
7.2 GELATIN CAPSULES MARKET, BY RAW MATERIAL
7.2.1 PORCINE GELATIN
7.2.1.1 Cost-effectiveness, high availability, and quick dissolving properties to support use in hard capsule production
7.2.2 BOVINE-DERIVED GELATIN
7.2.2.1 Reduced cattle slaughter to limit market growth
7.2.3 BONEMEAL GELATIN
7.2.3.1 Rising demand for bonemeal capsules in pharmaceutical industry to encourage market growth
7.2.4 OTHER GELATIN SOURCES
7.3 NON-GELATIN CAPSULES MARKET, BY RAW MATERIAL
7.3.1 HYDROXYPROPYL METHYLCELLULOSE (HPMC)
7.3.1.1 Chemical & thermal stability, faster dissolution, and low brittleness in low humidity to favor market growth
7.3.2 PULLULAN & STARCH
7.3.2.1 Increasing demand for transparent, vegan, and non-GMO capsules to accelerate market growth

8 EMPTY CAPSULES MARKET, BY FUNCTIONALITY
8.1 INTRODUCTION
8.2 IMMEDIATE-RELEASE CAPSULES
8.2.1 RAPID ABSORPTION, LOW PRODUCTION COST, AND BROAD APPLICATIONS TO AUGMENT MARKET GROWTH
8.3 SUSTAINED-RELEASE CAPSULES
8.3.1 CONTROLLED DRUG RELEASE FOR CHRONIC DISEASE MANAGEMENT TO SPUR MARKET GROWTH
8.4 DELAYED-RELEASE CAPSULES
8.4.1 DEMAND FOR ENTERIC-COATED CAPSULES AND ADVANCEMENTS IN PH-SENSITIVE POLYMER COATINGS TO DRIVE MARKET

9 EMPTY CAPULES MARKET, BY SIZE
9.1 INTRODUCTION
9.2 SIZE 0
9.2.1 RISING DEMAND FOR MID-DOSE FORMULATIONS TO FUEL MAKET GROWTH
9.3 SIZE 00
9.3.1 INCREASED NEED FOR ENCAPSULATING SINGLE-DOSE HERBAL EXTRACTS TO BOOST MARKET GROWTH
9.4 SIZE 1
9.4.1 NEED FOR COMPACT, LOW-TO-MID DOSE FORMULATIONS WITH HIGH SWALLOWABILITY TO BOOST ADOPTION
9.5 SIZE 2
9.5.1 DOSE ACCURACY, COMPATIBILITY WITH DIETARY PREFERENCES, AND STANDARD MANUFACTURING EQUIPMENT TO SPUR MARKET
9.6 SIZE 000
9.6.1 POPULARITY OF HIGH-DOSE CAPSULES IN SPORTS NUTRITION, FUNCTIONAL MEDICINES, AND HERBAL FORMULATIONS TO DRIVE MARKET
9.7 SIZE 3
9.7.1 NEED FOR PRECISE AND LOW-DOSE DELIVERY TO AUGMENT MARKET GROWTH
9.8 SIZE 4
9.8.1 FOCUS ON DOSE PERSONALIZATION AND PATIENT-CENTRIC CARE TO FUEL ADOPTION IN PEDIATRIC DOSING AND GERIATRIC MEDICATIONS
9.9 SIZE 5
9.9.1 MINIMAL CAPACITY AND SMALL FOOTPRINT TO BE USEFUL IN SPECIALTY SEGMENTS

10 EMPTY CAPSULES MARKET, BY THERAPEUTIC APPLICATION
10.1 INTRODUCTION
10.2 ANTIBIOTIC & ANTIBACTERIAL DRUGS
10.2.1 HIGH INCIDENCE OF INFECTIOUS DISEASES AND FOCUS ON INNOVATIVE CAPSULE FORMULATIONS TO DRIVE MARKET
10.3 DIETARY SUPPLEMENTS
10.3.1 HIGH UPTAKE OF MULTIVITAMINS TO BOOST MARKET DEMAND
10.4 ANTACID & ANTIFLATULENT PREPARATIONS
10.4.1 POPULARITY OF GENERIC MEDICATIONS AND LIFESTYLE CHANGES IN EMERGING ECONOMIES TO SPUR MARKET GROWTH
10.5 ANTIANEMIC PREPARATIONS
10.5.1 RISING PREVALENCE OF ANEMIA TO SUPPORT MARKET FOR IRON & FOLIC ACID DEFICIENCY CAPSULES
10.6 ANTI-INFLAMMATORY DRUGS
10.6.1 EXPANSION OF GENERIC THERAPEUTICS MARKET FOR OBESITY TO PROPEL MARKET GROWTH
10.7 CARDIOVASCULAR THERAPY DRUGS
10.7.1 SEDENTARY LIFESTYLE AND HIGH PREVALENCE OF DIABETES TO BOOST MARKET GROWTH
10.8 COUGH & COLD DRUGS
10.8.1 RISING ENVIRONMENTAL POLLUTION AND INCREASING NUMBER OF PASSIVE SMOKERS TO FAVOR MARKET GROWTH
10.9 OTHER THERAPEUTIC APPLICATIONS

11 EMPTY CAPSULES MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL INDUSTRY
11.2.1 INCREASING FOCUS ON ADVANCED DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET GROWTH
11.3 NUTRACEUTICAL INDUSTRY
11.3.1 GROWING DEMAND FOR DIETARY SUPPLEMENTS TO BOOST MARKET DEMAND
11.4 COSMETIC INDUSTRY
11.4.1 RISING FOCUS ON PERSONALIZED BEAUTY AND HOLISTIC WELLNESS TO SUPPORT MARKET GROWTH
11.5 RESEARCH LABORATORIES
11.5.1 GROWING FOCUS ON CLINICAL TRIALS TO SUPPORT ADOPTION IN PRECISE DOSING AND PHARMACEUTICAL TESTING

12 EMPTY CAPSULES MARKET, BY REGION
12.1 INTRODUCTION
12.1.1 GLOBAL EMPTY CAPSULES MARKET VOLUME
12.2 NORTH AMERICA
12.2.1 NORTH AMERICAN EMPTY CAPSULES VOLUME MARKET, BY TYPE
12.2.2 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.3 US
12.2.3.1 US to dominate North American empty capsules market during forecast period
12.2.4 CANADA
12.2.4.1 Rising per capita healthcare spending and growing elderly population to propel market growth
12.3 EUROPE
12.3.1 EUROPEAN EMPTY CAPSULES VOLUME MARKET, BY TYPE
12.3.2 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.3 GERMANY
12.3.3.1 Rising consumer demand for capsule-based pharma and nutraceutical formulations to aid market growth
12.3.4 UK
12.3.4.1 High demand for nutraceuticals and rapid shift toward plant-based lifestyles to augment market growth
12.3.5 FRANCE
12.3.5.1 Popularity of self-care trends and regulatory push for plant-based capsules to propel market growth
12.3.6 ITALY
12.3.6.1 High R&D spending in pharmaceutical manufacturing industry to support market growth
12.3.7 SPAIN
12.3.7.1 Low production costs and consolidation of biotechnology sector to fuel market growth
12.3.8 NETHERLANDS
12.3.8.1 Expanding clinical research activity and strong nutraceutical innovation ecosystem to drive market
12.3.9 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 ASIA PACIFIC EMPTY CAPSULES VOLUME MARKET, BY TYPE
12.4.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.3 CHINA
12.4.3.1 Rapidly growing pharmaceutical, cosmetic, and nutraceutical industries to augment market growth
12.4.4 INDIA
12.4.4.1 Surge in demand for dietary supplements and presence of highly skilled medical professionals to favor market growth
12.4.5 JAPAN
12.4.5.1 Increased demand for high-quality generic oral drugs to boost market demand
12.4.6 SOUTH KOREA
12.4.6.1 Increased government focus on domestic drug production and R&D to support market growth
12.4.7 AUSTRALIA
12.4.7.1 Rising incidence of chronic diseases among geriatric population and increasing demand for supplements to fuel market growth
12.4.8 NEW ZEALAND
12.4.8.1 Increasing prevalence of lifestyle-related disorders and expanding therapeutic supplement use to propel market growth
12.4.9 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 LATIN AMERICAN EMPTY CAPSULES VOLUME MARKET, BY TYPE
12.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.3 BRAZIL
12.5.3.1 High export of generics to support market growth
12.5.4 MEXICO
12.5.4.1 Well-developed healthcare regulatory environment and increased demand for chronic disease treatment to favor market growth
12.5.5 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MIDDLE EASTERN EMPTY CAPSULES VOLUME MARKET, BY TYPE
12.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
12.6.3 GCC COUNTRIES
12.6.3.1 Saudi Arabia
12.6.3.1.1 Favorable government-led healthcare reforms and increased pharmaceutical production capabilities to aid market growth
12.6.3.2 UAE
12.6.3.2.1 Favorable government strategies and high per capita health expenditure to fuel market growth
12.6.3.3 Rest of GCC Countries
12.6.4 REST OF MIDDLE EAST
12.7 AFRICA
12.7.1 DEVELOPMENT OF PHARMACEUTICAL SECTOR TO SPUR MARKET GROWTH
12.7.2 AFRICAN EMPTY CAPSULES VOLUME MARKET, BY TYPE
12.7.3 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN EMPTY CAPSULES MARKET, JANUARY 2022-JULY 2025
13.3 REVENUE ANALYSIS, 2020-2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.5.5.1 Company footprint
13.5.5.2 Region footprint
13.5.5.3 Type footprint
13.5.5.4 Functionality footprint
13.5.5.5 End-user footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING
13.6.5.1 Detailed list of key startups/SMEs
13.6.5.2 Competitive benchmarking of startups/SMEs
13.7 COMPANY VALUATION & FINANCIAL METRICS
13.7.1 FINANCIAL METRICS
13.7.2 COMPANY VALUATION
13.8 BRAND/PRODUCT COMPARISON
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES & APPROVALS
13.9.2 DEALS
13.9.3 EXPANSIONS
13.9.4 OTHER DEVELOPMENTS

14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 CAPSUGEL (LONZA)
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches
14.1.1.3.2 Other developments
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses & competitive threats
14.1.2 ACG
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Expansions
14.1.2.3.2 Other developments
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses & competitive threats
14.1.3 QUALICAPS (ROQUETTE FRERES)
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Deals
14.1.3.3.2 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses & competitive threats
14.1.4 SUHEUNG
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches & approvals
14.1.5 HEALTHCAPS INDIA
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.6 NECTAR LIFESCIENCES LTD.
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Deals
14.1.7 SUNIL HEALTHCARE LIMITED
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.8 NATURAL CAPSULES LIMITED
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.9 QINGDAO YIQING BIOTECHNOLOGY CO., LTD. (BAOTOU DONGBAO BIO-TECH CO., LTD.)
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches
14.1.10 COMED CHEMICALS LIMITED
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.11 ANHUI HUANGSHAN CAPSULE CO., LTD.
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.12 FORTCAPS (KUMAR ORGANIC PRODUCTS LIMITED)
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.12.3 Recent developments
14.1.12.3.1 Deals
14.1.13 SHANDONG HEALSEE CAPSULE LTD. (SHANDONG HEAD GROUP CO., LTD.)
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.14 CAPSCANADA
14.1.14.1 Business overview
14.1.14.2 Products offered
14.1.15 FARMACAPSULAS
14.1.15.1 Business overview
14.1.15.2 Products offered
14.1.16 SHANXI GUANGSHENG MEDICINAL CAPSULE CO., LTD.
14.1.16.1 Business overview
14.1.16.2 Products offered
14.1.16.3 Recent developments
14.1.16.3.1 Other developments
14.1.17 ERAWAT PHARMA LIMITED
14.1.17.1 Business overview
14.1.17.2 Products offered
14.2 OTHER PLAYERS
14.2.1 SAVIOURCAPS
14.2.2 SHANXI JC BIOLOGICAL TECHNOLOGY CO.
14.2.3 ROXLOR
14.2.4 MEDISCA INC.
14.2.5 ZHEJIANG YUEXI CAPSULE CO., LTD.
14.2.6 SHAOXING KANGKE CAPSULE CO., LTD.
14.2.7 ZHEJIANG HUILI CAPSULES CO., LTD.
14.2.8 SHAOXING ZHONGYA CAPSULE CO., LTD.
14.2.9 SHING LIH FANG ENTERPRISE CO., LTD.
14.2.10 LEFANCAPS
14.2.11 CHEMCAPS LIMITED
14.2.12 BIOCAPS ENTERPRISE
14.2.13 SNAIL PHARMA INDUSTRY
14.2.14 BRIGHT PHARMA CAPS
14.2.15 SHREE PHARMA CAPS
14.2.16 HEXIN CAPSULE CO., LTD.
14.2.17 WUHAN CARMA TECHNOLOGY CO., LTD.
14.2.18 AIPAK PHARMA

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS